EP1003851A2 - Rsv epitope und antikörper dagegen zur verwendung in dagnose und therapie - Google Patents

Rsv epitope und antikörper dagegen zur verwendung in dagnose und therapie

Info

Publication number
EP1003851A2
EP1003851A2 EP98939703A EP98939703A EP1003851A2 EP 1003851 A2 EP1003851 A2 EP 1003851A2 EP 98939703 A EP98939703 A EP 98939703A EP 98939703 A EP98939703 A EP 98939703A EP 1003851 A2 EP1003851 A2 EP 1003851A2
Authority
EP
European Patent Office
Prior art keywords
peptide
protein
rsv
nucleotide sequence
immunogenic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98939703A
Other languages
English (en)
French (fr)
Inventor
Thien Ngoc Nguyen
Ultan Power
Liliane Goestch
Alain Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of EP1003851A2 publication Critical patent/EP1003851A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to respiratory syncytial virus, and. more particularly to the identification of new epitopes and to the corresponding antibodies, useful in particular in the field of treatment, prophylaxis and diagnosis of the conditions caused by this virus.
  • Respiratory syncytial virus is one of the most common etiological agents encountered in infants and the elderly. Bronchiolitis is often severe in children and requires hospitalization. Currently, there are no means of prevention against RSV disease, the first RSV infection does not prevent against the next. Treatment of severe cases with antibiotic therapy (Ribavirin) and / or combined with immunotherapy (human immunoglobulins) cannot reduce the worsening of the disease. However, this type of treatment is still very expensive. Recent clinical trials with ORAVAX HNK20 monoclonal antibodies (directed against RSV F protein) have not shown efficacy compared to placebo against RSV infection in children.
  • RSV is classified in the family of Paramyxoviridae, genus pneumovirus comprising a non-segmented RNA genome, of negative polarity, coding for 10 specific proteins.
  • Application WO 87/04185 proposed using RSV structural proteins for a vaccine, such as the envelope proteins called protein F (fusion protein) or protein G, a 22 Kd glycoprotein, a protein of 9.5 Kd, or the major capsid protein (protein N).
  • RSV protein G can be useful in the preparation of products intended for the treatment and / or prevention of disorders caused by RSV, subgroup A or B.
  • fragments of the RSV protein G containing specific epitopes, have particularly advantageous properties.
  • New peptide fragments of the RSV protein G can thus be prepared, in particular for the following applications: (i) said peptide fragment coupled or fused, by chemical methods or by genetic engineering, to a carrier, constitutes an effective vaccine against RSV infection, regardless of the mode of administration;
  • the same peptide fragments can be used to generate polyclonal and monoclonal antibodies which are very effective in the prophylactic or therapeutic treatments of the host infected with RSV;
  • these peptide fragments and the monoclonal antibodies can be used as reagents in a diagnostic kit allowing assert and identify infection in the host infected with RSV- ⁇ or RSV-B.
  • the subject of the invention is therefore polyclonal or monoclonal antibodies directed against an epitope of the G protein of RSV corresponding to a sequence chosen from one of the peptide sequences included respectively between the amino acid residues 150-159, 176-189 , 194-207 and 155-176 of the total sequence of protein G of RSV A or B, or of sequences having at least 80%, and preferably at least 98% of homology.
  • These antibodies will recognize peptides carried by the sequence between amino acid residues 130 and 230 of protein G of RSV, subgroup A or subgroup B.
  • G2Na This region corresponding to amino acids 130-230 of protein G of RSV A is hereinafter designated G2Na.
  • G2Na was produced in a bacterium such as E. coli, therefore not glycosylated. It confers, in particular when it is coupled to a carrier such as an OmpA of gram negative bacteria, for example of Klebsiella (protein p40, described in WO 96/14415) or a protein derived from streptococcus (such as the protein binding to serum albumin human, hereinafter called BB, described in WO 96/14416), an immune protection against RSV infections.
  • BB serum albumin human
  • a recombinant protein BBG2al a derivative of BBG2Na where only four residues have been modified on G2Na: the residues Asn (aal91), Lys (aal92), Gly (195) and Thr (aal98) have been replaced by the residues Ser , Asn, Lys and Pro respectively, confers VRS-A or VRS-B cross-protection in BALB / c mice.
  • BBG2a2 where the residues Asn (aal 57), Asn (aal60), ⁇ sn (aal61) and Phe (aal63) have been substituted by the residues Lys, Lys, ⁇ sp and Tyr respectively;
  • BBG2a3 contains the eight modified residues of BBG2a l and BBG2a2.
  • Particularly advantageous peptides according to the invention present in particular one of the sequences chosen from the sequences ID No. 1, ID No. 2, ID No. 3, ID No. 4, ID No. 5, ID No.
  • such a peptide can, in addition, comprise at least one cysteine residue in the N-terminal or C-terminal position.
  • G5a (aal44-159), G1a (aal64-176), G4a (aal72-187) and G9a (aal90-204).
  • the invention therefore also relates to antibodies, monoclonal or polyclonal, directed against a peptide having at least one of the sequences ID No. 1 to ID No. 22.
  • Peptides having one or more units corresponding to epitopes 150-159, 176-189, 194-207 and 155-176 of the GRS protein G sequence will be very useful for the various embodiments of the invention.
  • Peptides according to the invention, coupled to a carrier protein are useful as immunogens.
  • the carrier protein is advantageously chosen from the OmpA of gram negative bacteria and their fragments, the TT protein (tetanus toxoid), the human serum albumin binding protein of Streptococcus and its fragments and the B subunit of cholera toxin. (CTB); preferably, the carrier protein is an OmpA of a bacterium of the genus Klebsiella.
  • the peptide is conjugated to the carrier protein by a binding protein; this binding protein can in particular be chosen from a receptor for serum mammalian albumin and the receptors present on the surface of mucosal cells.
  • the coupling is preferably a covalent coupling, which can be carried out chemically or by recombinant DNA techniques.
  • the invention therefore relates to a nucleotide sequence coding for a peptide or an immunogenic agent as defined above. It may in particular be a hybrid DNA molecule produced by insertion or fusion into the DNA molecule coding for the carrier protein, DNA coding for a peptide according to one of claims 4 or 5 or l 'one of their fragments, fused with a promoter; it can also be an RNA molecule.
  • the peptides, antibodies, immunogens and nucleotide sequences according to the invention can be used as a medicament, and more particularly for the preparation of a composition intended for the preventive or curative treatment of conditions caused by RSV, group A or B.
  • monoclonal antibodies specifically recognizing the peptides G5a and G l ia and G l ⁇ Ca were generated. Passive transfer of monoclonal antibodies 5C2 (anti-G5a) and 18D 1 (anti-G l ⁇ Ca) to naive mice on the one hand prevents infection with RSV-A. And on the other hand, the same 5C2 monoclonal rapidly eliminates a chronic RSV-A infection in immunocompromised mice.
  • the subject of the invention is therefore also a pharmaceutical composition, characterized in that it contains at least one mono or polyclonal antibody, a peptide or an epitope according to the invention, an agent immunogen, or a nucleotide sequence as defined above, and pharmacologically acceptable excipients.
  • the monoclonal antibodies are preferably humanized and produced by the recombinant route. According to another aspect of the invention, they are obtained by the phage library method.
  • the peptides, immunogens, antibodies and nucleotide sequences according to the invention can, according to an embodiment of the invention, enter into the composition of a diagnostic kit.
  • the immunogens can be prepared by recombinant DNA technology, by the introduction of a nucleotide sequence according to the invention in a host cell.
  • This nucleotide sequence can be a fusion gene which is introduced via a DNA vector which comes from a plasmid, a bacteriophage, a virus and / or a cosmid.
  • This fusion gene can, in one embodiment of the preparation process, be integrated into the genome of the host cell.
  • the vector may be a viral vector, known to those skilled in the art.
  • the host cell can be a prokaryote, in particular chosen from the group comprising: E. coli, Bacillus, Lactobacillus, Staphylococcus and Streptococcus.
  • the host cell can also be a yeast, a mammalian cell, a cell of plant origin or an insect cell.
  • the fusion protein is expressed: secreted, localized in the cytoplasm, or else exposed to the membrane of the host cells.
  • Figures 1 and 2 Principle of cloning the genes G2a l, G2a2 and G2a3 in vectors.
  • Figure 3 A-SDS-P ⁇ GE 20% Gel, staining with Comassie Blue.
  • M Standards of molecular sizes, tracks 1 and 2 proteins BBG2a l (theoretical mass 38.7 Kd) purified by affinity on HSA-Sepharose.
  • Figure 5 A- Immunogenicity of peptides G7a and G8a.
  • Figure 6 Immunogenicity of BBG2al to RSV A ( Figure 6A) and RSV B (6B) and protective efficacy against RSV A (6C) and RSV B (6D).
  • Figure 7 Curative effect of monoclonal antibodies 18D 1 and 5C2.
  • Figure 8 A- Prophylactic efficacy of the 18D 1 monoclonal antibody.
  • Figure 10 Determination of the recognition zone of the 5B7 monoclonal antibody by the Pepscan B method.
  • BHA Bromo hydrosuccimidyl acid
  • CE Capillary Electrophoresis
  • FZCE Free Zone Capillary Electrophoresis
  • HBTU 2- (l H-Benzotriazole- l-yl) - l, l, 3,3-tetramethyluronium hexafluorophosphate
  • the peptide G5a is a peptide of 16 amino acids which corresponds to the fragment of the protein G (144-159) of the VRS-A. It is obtained by chemical synthesis on solid phase from the C side to the N-terminal side.
  • the peptides CysG5a and G5aCys correspond respectively to this peptide with an additional Cysteine on the N or C-terminal side which is intended for unequivocal coupling on a carrier protein.
  • the peptides were synthesized using an automatic solid phase peptide synthesizer from the C side to the N-terminal side (FMOC chemistry on the scale of 0.1, 0.25 or 1.0 mmol).
  • the synthesis of the CysG5a peptide is carried out from a Proline preloaded on a resin of HMP type, which allows after cleavage to obtain a free acid function on the C-terminal side or a resin of Rink amide MHBA type, which allows after cleavage to obtain an amide function on the C-terminal side. That of the G5aCys peptide begins with a Cysteine preloaded on one or the other of the resins.
  • the reactive functions of the side chains of the amino acids used are protected by groups compatible with chemistry
  • a coupling cycle takes place as follows: deprotection of the N-terminal amino function of the first amino acid using piperidine, activation of the acid function of the second amino acid to be coupled using HBTU / HMP and coupling.
  • the peptide ' is cleaved from the resin and the side chains are deprotected by reaction with a water / TFA mixture.
  • the peptide is precipitated with ether cooled beforehand to -40 ° C and the mixture is centrifuged. The pellet is washed three times with ether and then dried with nitrogen. The pellet is taken up with water containing 0.1% TFA.
  • Example 2 Coupling of peptides G5a, G7a, G8a, G9a, Gl la and Gl l ⁇ Ca on a carrier protein (P40, BB, TT, KLH).
  • the peptide Gl l ⁇ Ca (Seq ID No. 14) is a peptide of 13 amino acids derived from protein G of the RSV. It corresponds to the sequence 164-176 of this protein. During the synthesis, the Cys residue at position 173 was replaced by a Ser residue in order to keep only one Cys residue in position 176 and avoid the formation of a disulfurc bridge 1 -2 which does not exist in natural protein G (apparently 1 -4 / 2-3).
  • This peptide was coupled using glutaraldehyde (homobifunctional reagent, coupling on the amino and thiol functions) or unequivocally using BH ⁇ (heterobi onctional reagent, coupling on the thiol function of Cysteine in position C- terminal).
  • the solution is then dialyzed using a 0.1 M phosphate buffer, pH 7 + 0.1% Zwittergent 3-14, overnight at + 4 ° C. with stirring and the solution obtained is stored frozen. • Coupling to the P40 protein using a homobifunctional reagent (glutaraldehyde).
  • conjugates are thawed, sterile filtered (0.22 ⁇ m), aliquoted and stored at + 4 ° C to avoid problems of precipitation.
  • the conjugates are characterized by assaying the proteins by the Lowry method, electrophoresis of the SDS-PAGE type (development with Coomassie blue) and by assaying the amino acids after acid hydrolysis in the gas phase, derivation by PITC and analysis by HPLC.
  • Example 3 Cloning of G2al, G2a2 gene in expression vector pvaBB308 and production of BBG2al and BBG2a2 fusion proteins in E. coli
  • the principle of cloning of G2al gene (Seq ID No. 15), G2a2 (Seq ID No. 16 ) and G2a3 (Seq ID No. 17) in the vectors is explained in Figures 1 and 2.
  • G2al The gene coding for the protein G2al (Seq ID No. 15) is constructed by site-directed mutagenesis using the plasmid pRIT28G2Na as starting material. For this, two PCR reactions (Polymerase chain reaction) are carried out with the pairs of oligonucleotides RIT29 / TH 137 (PCR 1) on the one hand and RIT30 / TH 136 (PCR 2) on the other hand under the following conditions:
  • the fragments obtained, respectively 262 bp and 208 bp for reactions 1 and 2 are fixed on magnetic beads.
  • 25 ⁇ l of DYNAL® M-280 magnetic beads coupled to streptavidin are rinsed twice beforehand with TE buffer (10 mM Tris; EDTA ImM, pH 7.5) and then incubated for 20 minutes at 37 ° C with 90 ⁇ l of amplification reactions 1 and 2.
  • the fragments are denatured by incubating the magnetic beads with 50 ⁇ l of 0.15 M NaOH for 10 minutes at room temperature. The two supernatants are recovered, precipitated with absolute ethanol and resuspended in 50 ⁇ l of I ⁇ O.
  • the amplified fragment of 509 bp is digested with the restriction enzymes Psû and HindIII.
  • the generated fragment of 169 bp is cloned in the vector pRIT28 digested with the same enzymes.
  • the plasmid obtained pRIT28G2al down is sequenced with the Dye Deoxy Terminator chemistry according to the protocol described by Applied Biosystem (Perkin Elmer).
  • the plasmid pRIT28G2al is obtained by cloning the PstI / Hindlll fragment from pRIT28G2aldown (fragment downstream of the Pst 1 site) into the vector pRIT28G2Na.
  • the G2al gene is then cloned into the expression vector pvaBB308 at the EcoRI / HindIII restriction sites generating the vector pvaBBG2al.
  • oligonucleotide sequence list is shown below: RIT27: 5 '- GCTTCCGGCTCGTATGTTGTGTG - 3'
  • TH 136 5'- CCG ⁇ GA ⁇ AAACCG ⁇ CGACC ⁇ ACCG ⁇ CC - 3 ' ⁇ -1137: 5' - TTTIT ⁇ CTTCGGTITGTTGJCTCGGG - 3 'RIT29: RIT27 biotinylated in 5' RIT30: RIT28 biotinylated in 5 '
  • oligonucleotides used in this construction are the following: RIT29 / TNG 193 (PCR 1) on the one hand and TNG 192 / RIT30 (PCR 2) on the other go.
  • PCR 1 RIT29 / TNG 193
  • TNG 192 / RIT30 PCR 2
  • sequences of the oligonucleotides are described below:
  • TNG 192 5'- CCGCCGAAAAAACCGAAAGACGAT - 3 '
  • TNG 193 5 '- CGAAATGGTAATCGTCTTTCGG - 3'
  • the three insert fragments G2al, G2a2 and G2a3 were cloned into different expression vectors in E. coli, in particular in our examples the vectors pvaBB308 where BB is the gene coding for the albumin receptor.
  • the fusion proteins obtained BBG2al, BBG2a2 and BBG2a3 can be easily purified by affinity on an HSA-Sepharose column (Human serum Albumin).
  • the parameters controlled during fermentation are: pH, agitation, temperature, oxygenation rate, feeding of combined sources (glycerol or glucose).
  • the pH is regulated at 7.0.
  • the temperature is set at 37 ° C.
  • a 30 g fraction of wet biomass is resuspended in 70 ml of TST solution (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 0.05% Tween 20 and 0.5 mM EDTA).
  • the cells are disintegrated by sonication (Vibracell 72401, Sonics & Materials). After centrifugation of the cell lysate, the supernatant is filtered (1.2 ⁇ m) and diluted in 500 ml of TST.
  • the fusion proteins thus obtained in soluble form are purified on an affinity column: HSA-Sepharose (human serum albumin) according to the protocol described by (Stahl et al, J. Immunol. Methods, 1989; 124: 43-52).
  • the insoluble lysate after centrifugation, is washed once with a buffer (50 mM Tris-HCl pH 8.5; 5 mM MgCl 2 ). After washing, the pellet is dissolved in 30 ml of 7 M guanidine hydrochloride, 25 mM Tris-HCl (pH 8.5), 10 mM Dithiotreitol (DTT), followed by incubation at 37 ° C for 2 hours. The solubilized proteins are added to a renaturation buffer (25 mM Tris-HCl (pH 8.5); 150 mM NaCl and 0.05% Tween 20).
  • the concentration of guanidine hydrochloride is adjusted to the final concentration of 0.5 M in the renaturation buffer before the addition of the solubilized fusion proteins.
  • the mixture is incubated at room temperature, with moderate shaking, for 16 hours. After centrifugation, the soluble products in the supernatant are purified on an HSA-Sepharose column.
  • the purified fusion proteins are analyzed on SDS-PAGE gel (12%), on the MINI PROTEAN II SYSTEM device (BIORADS). Proteins are visualized with Coomassie brilliant blue R250.
  • the analysis of the recombinant proteins by Immunoblot with antibodies specific for RSV shows that the proteins are antigenic (see example of SDS gel and BBG2al immunoblot in FIG. 3).
  • Example 4 Immunogenicity and protective efficacy of peptides G5a and G9a coupled to P40.
  • mice Groups of 7 mice were immunized twice ip with 20 ⁇ g of P40-G9aCys, P40-CysG5a, or P40-G5aCys. Control mice were immunized with PBS. Alhygrogel (20% v / v) was used as an adjuvant for all immunizations. The mice were taken from the retro-orbital sinus 2 weeks after the last immunization to confirm their seroconvcrsion against VRS-V, challenged a week later with 10 5 TCID 50 VRS- ⁇ by the in route, and sacrificed 5 days post-challenge . The lungs were removed and the titer of virus in the lungs determined.
  • the immunogenicity of the G5a peptide is dependent on the orientation of the coupling to P40. After coupling by the C-terminal part of the peptide, low to moderate anti-RSV-A antibody titers were induced in the serum. On the other hand, after coupling by the N-terminal part, G5a did not induce such antibodies.
  • the G9a peptide, coupled in C-terminal to P40 was weakly immunogenic in terms of induction of anti-RSV-A antibodies.
  • P40-G9acys developed a high anti-RSV-A antibody titer.
  • mice out of 7 immunized with P40-G5acys were protected without evidence of virus in the lungs, the last one had the virus only at the limit of detection of the test.
  • mice immunized with P40-cysG5a had virus titers in the lungs as high as control mice, immunized with PBS.
  • the peptides G5a and G9a contain protective epitopes against an RSV-A infection of the lungs.
  • the orientation of the coupling of G5a to a carrier protein is crucial for its protective efficacy.
  • Example 5 Immunogenicity and protective efficacy of peptides G7a and G8a.
  • mice Groups of 3 to 4 mice were immunized twice ip with 20 ⁇ g of G7a, G8a, BB-G7a, or BB-G8a.
  • Control mice were immunized with PBS.
  • Alhygrogel (20% v / v) was used as an adjuvant for all immunizations.
  • the mice were removed from the retro-orbital sinus 2 weeks after the last immunization to confirm their seroconversion vis-à-vis VRS-A, challenged a week later with 10 TCID 50 VRS-A by the inhalation route, and sacrificed for 5 days. post-challenge.
  • the lungs were removed and the nasal passages washed. The virus titers in the lungs and nasal passages were determined. Results - Humoral immune responses.
  • the peptides G7a and G8a are both immunogenic vis-à-vis the RSV- ⁇ coupled or not coupled to 1313. If we consider the titers of serum antibodies, the unlinked peptides seem to be a little more immunogenic than the coupled peptides.
  • the G7a and G8a peptides contain protective epitopes against the lungs.
  • the peptides are effective whether or not coupled to BB.
  • Example 6 Immunogenicity and protective efficacy of the BBG2al fusion protein.
  • mice were immunized 2 and 3 times, respectively, by ip route with 20 ⁇ g of protein 2 weeks apart .
  • Control mice were immunized with PBS.
  • Alhygrogel (20% v / v) was used as an adjuvant for all immunizations.
  • the mice were removed from the retro-orbital sinus 2 weeks after the last immunization to confirm their seroconversion with RSV-A, challenged a week later with 10 5 TCID 50 VRS- ⁇ by in route, and sacrifices 5 days post-challenge. The lungs were removed and the titer of virus in the lungs determined.
  • BBG2al is capable of inducing anti-RSV- ⁇ and B antibodies.
  • the anti-RSV- ⁇ antibody titer is much higher than the anti-RSV-B antibody titer. Nevertheless, antibody titers against the two strains of RSV are high.
  • mice challenged with VRS- ⁇ were protected without evidence of virus in the lungs (2 mice / 3) or only at the detection limit (1 mouse / 3).
  • the mice challenged with VRS-B were protected, either without evidence of virus in the lungs (1 mouse / 3) or with virus only at the detection limit (1 mouse / 3) or just above this detection limit (1 mouse / 3).
  • the BBG2al fusion protein is very immunogenic vis-à-vis VRS-A and vis-à-vis VRS-B.
  • BBG2al is capable of inducing responses which protect the lungs against a challenge with the 2 subgroups of RSV.
  • EXAMPLE 7 Obtaining the Antibodies 18D1, 5C2 and 5B7
  • Immunization peptide (i) G l ⁇ Ca coupled to KLI I (Kcyhole Lempct Haemocyanin), (ii) G2 ⁇ Ca and (iii) BBG2Na.
  • mice were immunized at OJ with 50 ⁇ g of CF ⁇ antigen (complete Freund Adjuvant) in ip, on D 14 with 10 ⁇ g of each antigen in IFA (Incomplete Freund Adjuvant) in ip, then on D38 in iv with 10 ⁇ g of each peptide without adjuvant.
  • the spleens are removed and fused with the myeloma cells SP2-O at D42 in a 1/1 ratio.
  • the hybridomas positive against each antigen are kept. These hybridomas were injected into mice to obtain ascites and then the different antibodies obtained were selected on different peptides in order to determine the specificity of the antibodies obtained.
  • the 18D 1, 5C2 monoclonal antibodies selected by their specificity against the peptides G l ⁇ Ca, G5a, specifically recognize VRS- ⁇ .
  • the monoclonal antibody 5B7 obtained from BBG2Na and recognizing the peptide G 1 recognizes it VRS-A.
  • Example 8 Curative effect of the 18D 1 and 5C2 monoclonal antibodies on chronic RSV-A infection obtained in SCID mice.
  • mice 10 5 TCID 50 of VRS-A, under 50 ⁇ l. Twenty-six days later, the mice received 50 ⁇ l of an 18D 1 antibody or 5C2 antibody preparation with an anti-RSV-A ELISA titre of 10 4, in and at the rate of 7 mice per group. . Control mice received anti-BB serum with an anti-BB ELISA titer of 10. The mice were sacrificed 5 days later and their lungs were removed for virus titration. Results.
  • Fig. 7 demonstrate that the 18D 1 and 5C2 monoclonal antibodies are capable of eliminating a chronic infection with VRS-A in SCID mice and this in a sterilizing manner. No traces of virus were detected in the lungs at the time of the sacrifice. The results obtained in the lungs of the mice treated with 5C2 correspond to the average of the detection limits of the test, a higher limit due to the lack of sample availability, and not to the presence of virus.
  • the monoclonal antibodies 5C2 and 18D 1 could be used as a therapeutic treatment in the context of pulmonary infections with RSV-A.
  • Example 9 Prophylactic effect of the 18D 1 monoclonal antibody on RSV-A infection in mice.
  • VRS-A received by intraperitoneal injection 200 ⁇ l of an 18D 1 antibody preparation adjusted for the anti-VRS-A ELISA titre of 10 ⁇ .
  • a group of ip transfer control mice received in parallel 200 ⁇ l of an anti-P40 serum preparation (irrelevant serum) adjusted to the anti-P40 ELISA titre of 10%. All the mice are infected the following day by the in route with 50 ⁇ l of a viral suspension containing 10 ⁇ TCID50 of VRS-A. They are sacrificed 5 days later for assay of virus in the lungs. Results.
  • the antibody 18 1 is capable after ip transfer of inducing protection in the lungs of naive mice during a challenge with VRS- ⁇ . All the mice are protected after injection of 200 ⁇ l of 18D 1 as 10 5 . Three out of 7 mice are protected without evidence of virus in the lungs. The others show traces of virus only at the detection limit of the trial (3 mice / 7), or just above this limit (1 mouse / 7). Control mice have titers between log i Q 3.70 and 4.45 per gram of lungs.
  • the 18D 1 antibody is capable of preventing a RSV-V pulmonary infection in B ⁇ LB / c mice. It demonstrates significant prophylactic efficacy.
  • Example 10 Prophylactic effect of 5C2 monoclonal antibody on RSV-A infection in mice.
  • Naive mice seronegative vis-à-vis VRS-A receive by transfer in, 50 ⁇ l of a preparation of 5C2 adjusted to the ELISA anti-VRS-A title of 10 4 .
  • Control mice receive in parallel anti-BB serum adjusted to the anti-BB ELISA titer of 10 4 . All mice are infected the next day by the in route with
  • mice treated with 5C2 at 10 4 were protected at the pulmonary level. Only 1 mouse out of 7 shows traces of virus. Control mice have titers between log i Q 3.70 and 4.70 per gram of lungs.
  • the 5C2 antibody is capable of preventing an RSV- ⁇ pulmonary infection in BALB / c mice. It demonstrates significant prophylactic efficacy.
  • Example 11 Pepscan: example of the multiple synthesis of 94 octapeptides covering the sequence of aa 130-230 of G2Na and overlapping with an amino acid.
  • peptides are synthesized on a solid support at the end of 96 "pins" (8 x 12) complementary to an ELISA microtiter plate in which the screening of monoclonal or polyclonal antibodies (sera) will be carried out directly.
  • control peptide # 1 PLAQGGGG A2 (l): control peptide # 2: GL ⁇ QGGGG
  • the synthesis corresponds to several cycles of deprotection, washing and coupling until the desired peptide sequences are obtained. At the end of the synthesis, the peptides are N-acetylated, before the step of deprotection of the side chains.
  • the amino acids used for synthesis on pins are protected by an Fmoc group (9-Fluorenylmethoxycarbonyl) and the following side chain protecting groups: t-Butyl ether (tBu) for Serine, Threonine and Tyrosine, t-Butyl ester (OtBu) for Aspartic and Glutamic Acids, t-Butoxycarbonyl (Boc) for Lysine, Histidine and Tryptophan, 2,2,5,7,8-pcntamethylchroman-6-sulfonyl (Pmc) for Arginine, Trityle (Trt) for Cysteine, Asparagine and Glutamine.
  • the activation of the acid function is carried out with Diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBt) dissolved in DMF.
  • DIC Diisopropylcarbodiimide
  • HOBt 1-hydroxybenzotriazole
  • Fmoc-amino acids undergo an activation step before they can be coupled.
  • the duration of a coupling step is 2 hours for a concentration of 100 mM with 1.5 equivalent of HOBt and 1.2 equivalent of DIC.
  • Software is used to calculate the quantities of reagents required for the coupling step.
  • the weighings are carried out in tubes classified in alphabetical order of the letter code of amino acids. The tubes are filled outside the balance on a sheet of paper-linen, then weighed until a mass close to that indicated on the weighing sheet is obtained. The mass must not be less than 0.2 mg nor more than 0.9 mg compared to the theoretical quantity.
  • Coupling step The pins are gently introduced into the wells. The box is closed carefully and left in a hood for the duration of the coupling for 2 hours for an amino acid concentration of 100 mM. A 2 hour coupling allows 3 couplings per day.
  • Acetylation of terminal amines the pine heads are incubated in the wells of a plate containing 150 ⁇ l of the following reactive mixture: DMF / acetic anhydride / trietylamine 50/5/1 (v / v / v). The block is enclosed in a box for 90 min. at room temperature. The block is then washed with 200 ml of MeOH for 15 min. then dried for 15 min.
  • the protective groups of the side chains are eliminated by immersing the pins in 200 ml of a TFA / anisole / Ethanedithiol 190/5/5 ml mixture for 2 h 30 at room temperature. After this deprotection step, the block of pins is removed from the acid solution. The box is rinsed once with MeOH, then filled with MeOH to completely immerse the block of pins in it for 10 min. The block is then struck on tissue paper and then immersed in 200 ml of a MeOH / water / acetic acid mixture (100/100/1 ml) for 1 hour and struck again on tissue paper. The block is placed under vacuum in a desiccator overnight.
  • Example 12 ELISA The plate carrying the pins is saturated for 1 hour at 37 ° C. in saturation buffer (PBS, Tween 0, 1%, gelatin 1%), washed for 10 min in PBS and incubated overnight at 4 ° C. with shaking. with the diluted serum to be analyzed. The plate is then washed 4 times 10 min in PBS and incubated for one hour at room temperature with a secondary antibody labeled with peroxidase, diluted to 1/5000 e. After 4 washes in PBS, the TMB substrate is added. The reaction is stopped by adding sulfuric acid.
  • saturation buffer PBS, Tween 0, 1%, gelatin 1%
  • FIGS. 9 ⁇ and 9B show a reactivity of the anti-BBG2Na mouse serum against 4 regions of the G2Na molecule (the residues in bold lines represent the amino acids playing an important role in ⁇ c / Ag recognition): - region 1 located between residues 150 and 159 whose sequence is QRQNKPPNKP. This region is included in the peptide G5a (144-159) and corresponds to the reactivity zone of the 5C2 monoclonal antibody;
  • Region 2 located between residues 176 and 189 whose sequence is CSNNPTCWAICKRI. It is a region located at the level of the peptide G l ⁇ Ca (174-187) and corresponding to the reactivity of the monoclonal antibodies 18D 1 and 5D3;
  • G l la the recognition zone of the monoclonal antibody 5B7 (obtained after immunization of BALB / c mice by the vaccine candidate BBG2Na) whose pepsean B is shown below in Figure 10.
  • This monoclonal antibody recognizes the sequence FEVFNFVP (165-172).
  • Table I shows that the anti-BBG2Na serum indeed exhibits "anti-G4a, G5a cys, G9a cys and Gl1a" activities.
  • Table I Anti-G4a, G5aCys, G9aCys and Gl l ⁇ Ca Titers Expressed in Logio of the Anti-BBG2Na Serum Ref. BE-02.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98939703A 1997-07-17 1998-07-17 Rsv epitope und antikörper dagegen zur verwendung in dagnose und therapie Withdrawn EP1003851A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9709079A FR2766192B1 (fr) 1997-07-17 1997-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR9709079 1997-07-17
PCT/FR1998/001570 WO1999003987A2 (fr) 1997-07-17 1998-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie

Publications (1)

Publication Number Publication Date
EP1003851A2 true EP1003851A2 (de) 2000-05-31

Family

ID=9509314

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98939703A Withdrawn EP1003851A2 (de) 1997-07-17 1998-07-17 Rsv epitope und antikörper dagegen zur verwendung in dagnose und therapie

Country Status (8)

Country Link
EP (1) EP1003851A2 (de)
JP (1) JP2001510039A (de)
CN (1) CN1264425A (de)
AU (1) AU756110B2 (de)
BR (1) BR9810907A (de)
CA (1) CA2296736A1 (de)
FR (1) FR2766192B1 (de)
WO (1) WO1999003987A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
GB9920000D0 (en) * 1999-08-25 1999-10-27 Imp Cancer Res Tech Polypeptides
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
EP1174506A1 (de) * 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminales Erns-Peptide und Analoge davon
FR2819810B1 (fr) * 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
SI1472286T1 (sl) * 2002-02-05 2007-08-31 Geymonat Spa Postopek proizvodnje rekombinantnega placentnega rastnega faktorja
CN100528896C (zh) * 2004-02-03 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 用于预防、诊断和治疗呼吸道合胞病毒感染的嵌合抗原及其抗体
EP1768993A4 (de) * 2004-06-16 2008-07-23 Univ Johns Hopkins Cysteinreiche region des humanen respiratorischen synzytial-virus und verwendungsverfahren dafür
CN101130765B (zh) * 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 呼吸道合胞病毒检测试剂盒
CN101808663B (zh) * 2007-10-25 2015-09-30 特雷利斯生物科学股份有限公司 抗rsv g蛋白抗体
EP2461825B1 (de) * 2009-08-04 2017-05-31 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Anti-rsv-immunogene und immunisierungsverfahren damit
CN103163302B (zh) * 2011-12-10 2015-06-03 河北菲尼斯生物技术有限公司 一种采用定向交叉偶联技术制备的短肽抗体试剂盒
CN106432439A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106397547A (zh) * 2016-11-28 2017-02-15 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106518988A (zh) * 2016-11-28 2017-03-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749555A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432437A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432438A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432436A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432435A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749556A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN112409481B (zh) * 2020-12-01 2024-03-26 福州捷赫生物科技有限公司 抗p40蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
SE9101433D0 (sv) * 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69509103T2 (de) * 1994-08-25 1999-09-30 Pepscan Systems Bv Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv-infektionen
FR2726576B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9903987A2 *

Also Published As

Publication number Publication date
FR2766192A1 (fr) 1999-01-22
WO1999003987A2 (fr) 1999-01-28
AU756110B2 (en) 2003-01-02
BR9810907A (pt) 2000-08-01
CA2296736A1 (fr) 1999-01-28
WO1999003987A3 (fr) 1999-04-08
CN1264425A (zh) 2000-08-23
AU8812398A (en) 1999-02-10
JP2001510039A (ja) 2001-07-31
FR2766192B1 (fr) 2001-07-13

Similar Documents

Publication Publication Date Title
EP1003851A2 (de) Rsv epitope und antikörper dagegen zur verwendung in dagnose und therapie
EP0754231B1 (de) Peptidfragment des g-proteins des respiratorischen syncytialvirus, immunogene verbindung und pharmazeutische zusammensetzung, die es enthalten, und herstellungsverfahren
EP0791064B1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
EP0712414A1 (de) Rekombinanter vektor mit gensequenz von lipoproteine zur nukleotidefrequenzen expression
JPH03502687A (ja) レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法
BE1000811A4 (fr) Anticorps monoclonaux, peptides et compositions les contenant, destinees au diagnostic et au traitement des infections par le virus hiv.
NO313917B1 (no) Antigen-presenterende kapsid med fusert MS2-kappeprotein
ES2270420T3 (es) Genes receptores de la transferrina de haemophilus.
FR2827605A1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP0791063B1 (de) Trägerprotein mit adjuvant aktivität, diese enthaltende immunogene komplexe, ihre herstellung, nukleotidsequenz und impfstoff
JP2002511847A (ja) Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓに関連した歯周病の診断および治療のための合成ペプチド構築物
KR20090092764A (ko) 신규한 리노바이러스 중화 면역원 및 이의 백신 용도로의 이용
JPH03128399A (ja) エイズ用複合免疫原
WO2003102170A1 (fr) Souches de bordetella rendues deficientes par attenuation genetique
CA2385404A1 (fr) Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
EP0953050A1 (de) Mittel zum diagnostik, zur vorbeugung und zur behandlung von ansteckungenoder infektionen durch mucotrophe virusen
FR2650954A1 (fr) Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
FR2532850A1 (fr) Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention
JP2002518033A (ja) 農場動物の成長促進のための合成ソマトスタチン免疫原
MXPA00000587A (en) Epitopes of syndrical respiratory virus and antibodies that understand them, useful in diagnosis and tera
FR2699538A1 (fr) Sous-unité d'une capsule protéique CS31A modifiée par au moins un peptide hétérologue, capsule protéique CS31A et microorganismes portant ces sous-unités; procédés d'obtention et utilisation de ceux-ci.
WO1989006971A1 (en) Conserved rotavirus gene segments and use in immunization and neutralization

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000131

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050201